{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:20:46Z","timestamp":1789161646396,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Post-transplant cyclophosphamide (PTCy) has emerged as a promising graft-versus-host disease (GvHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, no studies have reported the efficacy of a GvHD prophylaxis based on PTCy with sirolimus (Sir-PTCy) in patients with acute myeloid leukemia (AML). In this retrospective study, we analyze the use of sirolimus in combination with PTCy, with or without mycophenolate mofetil (MMF), on 242 consecutive adult patients with AML undergoing a myeloablative first allo-HSCT from different donor types, in three European centers between January 2017 and December 2020. Seventy-seven (32%) patients received allo-HSCT from HLA-matched sibling donor, 101 (42%) from HLA-matched and mismatched unrelated donor, and 64 (26%) from haploidentical donor. Except for neutrophil and platelet engraftment, which was slower in the haploidentical cohort, no significant differences were observed in major transplant outcomes according to donor type in univariate and multivariate analysis. GvHD prophylaxis with Sir-PTCy, with or without MMF, is safe and effective in patients with AML undergoing myeloablative allo-HSCT, resulting in low rates of transplant-related mortality, relapse\/progression, and acute and chronic GvHD in all donor settings.<\/jats:p>","DOI":"10.1038\/s41409-022-01725-3","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T11:13:09Z","timestamp":1654773189000},"page":"1389-1398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia"],"prefix":"10.1038","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0844-0708","authenticated-orcid":false,"given":"Lorenzo","family":"Lazzari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitana","family":"Balaguer-Rosell\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0024-8068","authenticated-orcid":false,"given":"Juan","family":"Montoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6117-5328","authenticated-orcid":false,"given":"Raffaella","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Hernani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1382-6939","authenticated-orcid":false,"given":"Maria Teresa","family":"Lupo-Stanghellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Villalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Facal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5978-2578","authenticated-orcid":false,"given":"Manuel","family":"Guerreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5908-0792","authenticated-orcid":false,"given":"Simona","family":"Piemontese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8533-2562","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"Pi\u00f1ana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1489-1177","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3702-0817","authenticated-orcid":false,"given":"Carlos","family":"Solano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-768X","authenticated-orcid":false,"given":"Javier","family":"de la Rubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Peccatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-4619","authenticated-orcid":false,"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"1725_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641\u201350. https:\/\/doi.org\/10.1016\/j.bbmt.2008.03.005","journal-title":"Biol Blood Marrow Transpl"},{"key":"1725_CR2","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","volume":"124","author":"CG Kanakry","year":"2014","unstructured":"Kanakry CG, Tsai HL, Bola\u00f1os-Meade J, Smith BD, Gojo I, Kanakry JA, et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014;124:3817\u201327. https:\/\/doi.org\/10.1182\/blood-2014-07-587477","journal-title":"Blood"},{"key":"1725_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","volume":"11","author":"A Ruggeri","year":"2018","unstructured":"Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen JJ, Elmaagacli A, et al. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. J Hematol Oncol. 2018;11:40 https:\/\/doi.org\/10.1186\/s13045-018-0586-4","journal-title":"J Hematol Oncol"},{"key":"1725_CR4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41375-020-0863-4","volume":"35","author":"F Lorentino","year":"2021","unstructured":"Lorentino F, Labopin M, Ciceri F, Vago L, Fleischhauer K, Afanasyev B, et al. Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9\/10 or 10\/10 HLA-matched unrelated donors for acute leukemia. Leukemia. 2021;35:585\u201394. https:\/\/doi.org\/10.1038\/s41375-020-0863-4","journal-title":"Leukemia"},{"key":"1725_CR5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","volume":"127","author":"M Mielcarek","year":"2016","unstructured":"Mielcarek M, Furlong T, O\u2019Donnell PV, Storer BE, McCune JS, Storb R, et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood. 2016;127:1502\u20138. https:\/\/doi.org\/10.1182\/blood-2015-10-672071","journal-title":"Blood"},{"key":"1725_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","volume":"13","author":"J Sanz","year":"2020","unstructured":"Sanz J, Galimard JE, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol. 2020;13:46. https:\/\/doi.org\/10.1186\/s13045-020-00882-6","journal-title":"J Hematol Oncol"},{"key":"1725_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3324\/haematol.2016.151779","volume":"102","author":"A Ruggeri","year":"2017","unstructured":"Ruggeri A, Sun Y, Labopin M, Bacigalupo A, Lorentino F, Arcese W, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant. Haematologica. 2017;102:401\u201310. https:\/\/doi.org\/10.3324\/haematol.2016.151779","journal-title":"Haematologica"},{"key":"1725_CR8","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.bbmt.2015.04.025","volume":"21","author":"N Cieri","year":"2015","unstructured":"Cieri N, Greco R, Crucitti L, Morelli M, Giglio F, Levati G, et al. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. Biol Blood Marrow Transpl. 2015;21:1506\u201314. https:\/\/doi.org\/10.1016\/j.bbmt.2015.04.025","journal-title":"Biol Blood Marrow Transpl"},{"key":"1725_CR9","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1182\/bloodadvances.2020003779","volume":"5","author":"N Bejanyan","year":"2021","unstructured":"Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, et al. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv. 2021;5:1154\u201363. https:\/\/doi.org\/10.1182\/bloodadvances.2020003779","journal-title":"Blood Adv"},{"key":"1725_CR10","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.bbmt.2014.07.020","volume":"20","author":"SR Solomon","year":"2014","unstructured":"Solomon SR, Sanacore M, Zhang X, Brown S, Holland K, Morris LE, et al. Calcineurin inhibitor\u2013free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. Biol Blood Marrow Transpl. 2014;20:1828\u201334. https:\/\/doi.org\/10.1016\/j.bbmt.2014.07.020","journal-title":"Biol Blood Marrow Transpl"},{"key":"1725_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jha2.183","volume":"2","author":"R Hernani","year":"2021","unstructured":"Hernani R, Pi\u00f1ana JL, P\u00e9rez A, Quintero A, Montoro J, Hern\u00e1ndez-Boluda JC, et al. Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. EJHaem. 2021;2:236\u201348. https:\/\/doi.org\/10.1002\/jha2.183","journal-title":"EJHaem"},{"key":"1725_CR12","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood-2016-06-723205","volume":"128","author":"R Greco","year":"2016","unstructured":"Greco R, Lorentino F, Morelli M, Giglio F, Mannina D, Assanelli A, et al. Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. Blood. 2016;128:1528\u201331. https:\/\/doi.org\/10.1182\/blood-2016-06-723205","journal-title":"Blood"},{"key":"1725_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1034\/j.1600-6143.2002.20507.x","volume":"2","author":"JM Morales","year":"2002","unstructured":"Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transpl. 2002;2:436\u201342. https:\/\/doi.org\/10.1034\/j.1600-6143.2002.20507.x","journal-title":"Am J Transpl"},{"key":"1725_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1182\/blood-2006-01-0329","volume":"108","author":"R Zeiser","year":"2006","unstructured":"Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood. 2006;108:390\u20139. https:\/\/doi.org\/10.1182\/blood-2006-01-0329","journal-title":"Blood"},{"key":"1725_CR15","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/leu.2014.180","volume":"29","author":"J Peccatori","year":"2015","unstructured":"Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MTL, et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia. 2015;29:396\u2013405. https:\/\/doi.org\/10.1038\/leu.2014.180","journal-title":"Leukemia"},{"key":"1725_CR16","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1038\/s41409-020-0921-6","volume":"55","author":"J Montoro","year":"2020","unstructured":"Montoro J, Pi\u00f1ana JL, Hern\u00e1ndez-Boluda JC, Hernani R, Lorenzo I, P\u00e9rez A, et al. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transpl. 2020;55:2147\u201359. https:\/\/doi.org\/10.1038\/s41409-020-0921-6","journal-title":"Bone Marrow Transpl"},{"key":"1725_CR17","doi-asserted-by":"publisher","first-page":"776.e1","DOI":"10.1016\/j.jtct.2021.05.023","volume":"27","author":"R Greco","year":"2021","unstructured":"Greco R, Lorentino F, Albanese S, Lupo Stanghellini MT, Giglio F, Piemontese S, et al. Posttransplantation cyclophosphamide- and sirolimus-based graft-versus-host-disease prophylaxis in allogeneic stem cell transplant. Transpl Cell Ther. 2021;27:776.e1\u2013776.e13. https:\/\/doi.org\/10.1016\/j.jtct.2021.05.023","journal-title":"Transpl Cell Ther"},{"key":"1725_CR18","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transpl. 2020;55:1114\u201325. https:\/\/doi.org\/10.1038\/s41409-020-0803-y","journal-title":"Bone Marrow Transpl"},{"key":"1725_CR19","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628\u201333. https:\/\/doi.org\/10.1016\/j.bbmt.2009.07.004","journal-title":"Biol Blood Marrow Transpl"},{"key":"1725_CR20","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/s41409-018-0183-8","volume":"53","author":"A Mussetti","year":"2018","unstructured":"Mussetti A, De Philippis C, Carniti C, Bastos-Oreiro M, Gayoso J, Cieri N, et al. CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. Bone Marrow Transpl. 2018;53:1522\u201331. https:\/\/doi.org\/10.1038\/s41409-018-0183-8","journal-title":"Bone Marrow Transpl"},{"key":"1725_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41409-021-01486-5","volume":"57","author":"E Xue","year":"2022","unstructured":"Xue E, Lorentino F, Clerici D, Farina F, Oltolini C, Giglio F, et al. Coadministration of letermovir and sirolimus in allogeneic hematopoietic cell transplant recipients. Bone Marrow Transpl. 2022;57:128\u201330. https:\/\/doi.org\/10.1038\/s41409-021-01486-5","journal-title":"Bone Marrow Transpl"},{"key":"1725_CR22","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","volume":"120","author":"P Armand","year":"2012","unstructured":"Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012;120:905\u201313. https:\/\/doi.org\/10.1182\/blood-2012-03-418202","journal-title":"Blood"},{"key":"1725_CR23","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664\u201371. https:\/\/doi.org\/10.1182\/blood-2014-01-552984","journal-title":"Blood"},{"key":"1725_CR24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"1725_CR25","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, B\u00e9ne MC, Buccisano F, Cloos J, et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275\u201391. https:\/\/doi.org\/10.1182\/blood-2017-09-801498","journal-title":"Blood"},{"key":"1725_CR26","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"key":"1725_CR27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295\u2013304. https:\/\/doi.org\/10.1097\/00007890-197410000-00001","journal-title":"Transplantation"},{"key":"1725_CR28","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945\u201356. https:\/\/doi.org\/10.1016\/j.bbmt.2005.09.004","journal-title":"Biol Blood Marrow Transpl"},{"key":"1725_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87\u201391. https:\/\/doi.org\/10.1093\/cid\/ciw668","journal-title":"Clin Infect Dis"},{"key":"1725_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3324\/haematol.2016.144428","volume":"101","author":"J Styczynski","year":"2016","unstructured":"Styczynski J, Van Der Velden W, Fox CP, Engelhard D, De La Camara R, Cordonnier C, et al. Management of epstein-barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European conference on infections in leukemia (ECIL-6) guidelines. Haematologica. 2016;101:803\u201311. https:\/\/doi.org\/10.3324\/haematol.2016.144428","journal-title":"Haematologica"},{"key":"1725_CR31","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813\u201321. https:\/\/doi.org\/10.1086\/588660","journal-title":"Clin Infect Dis"},{"key":"1725_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jac\/dkx324","volume":"73","author":"S Cesaro","year":"2018","unstructured":"Cesaro S, Dalianis T, Rinaldo CH, Koskenvuo M, Pegoraro A, Einsele H, et al. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2018;73:12\u201321. https:\/\/doi.org\/10.1093\/jac\/dkx324","journal-title":"J Antimicrob Chemother"},{"key":"1725_CR33","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the european society for blood and marrow transplantation. Bone Marrow Transpl. 2016;51:906\u201312. https:\/\/doi.org\/10.1038\/bmt.2016.130","journal-title":"Bone Marrow Transpl"},{"key":"1725_CR34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2307\/2281868","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457 https:\/\/doi.org\/10.2307\/2281868","journal-title":"J Am Stat Assoc"},{"key":"1725_CR35","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163\u201370.","journal-title":"Cancer Chemother Rep."},{"key":"1725_CR36","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509. https:\/\/doi.org\/10.1080\/01621459.1999.10474144","journal-title":"J Am Stat Assoc"},{"key":"1725_CR37","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","volume":"7","author":"DW Beelen","year":"2020","unstructured":"Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Rem\u00e9nyi P, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020;7:e28\u2013e39. https:\/\/doi.org\/10.1016\/S2352-3026(19)30157-7","journal-title":"Lancet Haematol."},{"key":"1725_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cncr.33255","volume":"127","author":"G Battipaglia","year":"2021","unstructured":"Battipaglia G, Labopin M, Hamladji RM, Blaise D, Chevallier P, Brissot E, et al. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2021;127:209\u201318. https:\/\/doi.org\/10.1002\/cncr.33255","journal-title":"Cancer"},{"key":"1725_CR39","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","volume":"16","author":"A Rambaldi","year":"2015","unstructured":"Rambaldi A, Grassi A, Masciulli A, Boschini C, Mic\u00f2 MC, Busca A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16:1525\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(15)00200-4","journal-title":"Lancet Oncol"},{"key":"1725_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/S13045-020-00923-0","volume":"13","author":"E Brissot","year":"2020","unstructured":"Brissot E, Labopin M, Moiseev I, Cornelissen JJ, Meijer E, Van Gorkom G, et al. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10\/10 HLA-matched unrelated donors. J Hematol Oncol. 2020;13:87. https:\/\/doi.org\/10.1186\/S13045-020-00923-0","journal-title":"J Hematol Oncol"},{"key":"1725_CR41","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood.V96.6.2062","volume":"96","author":"RA Nash","year":"2000","unstructured":"Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062\u20138. https:\/\/doi.org\/10.1182\/blood.V96.6.2062","journal-title":"Blood."},{"key":"1725_CR42","doi-asserted-by":"publisher","first-page":"483.e1","DOI":"10.1016\/J.JTCT.2021.02.031","volume":"27","author":"BL Scott","year":"2021","unstructured":"Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, et al. Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes\u2014long-term follow-up of the BMT CTN 0901 clinical trial. Transpl Cell Ther. 2021;27:483.e1\u2013483.e6. https:\/\/doi.org\/10.1016\/J.JTCT.2021.02.031","journal-title":"Transpl Cell Ther"},{"key":"1725_CR43","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/BLOOD-2015-04-639831","volume":"126","author":"SO Ciurea","year":"2015","unstructured":"Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033\u201340. https:\/\/doi.org\/10.1182\/BLOOD-2015-04-639831","journal-title":"Blood"},{"key":"1725_CR44","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/J.BBMT.2012.06.019","volume":"18","author":"SR Solomon","year":"2012","unstructured":"Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transpl. 2012;18:1859\u201366. https:\/\/doi.org\/10.1016\/J.BBMT.2012.06.019","journal-title":"Biol Blood Marrow Transpl"},{"key":"1725_CR45","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","volume":"31","author":"A Bashey","year":"2013","unstructured":"Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31:1310\u20136. https:\/\/doi.org\/10.1200\/JCO.2012.44.3523","journal-title":"J Clin Oncol"},{"key":"1725_CR46","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.bbmt.2015.06.008","volume":"21","author":"J Sugita","year":"2015","unstructured":"Sugita J, Kawashima N, Fujisaki T, Kakihana K, Ota S, Matsuo K, et al. HLA-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after busulfan-containing reduced-intensity conditioning. Biol Blood Marrow Transpl. 2015;21:1646\u201352. https:\/\/doi.org\/10.1016\/j.bbmt.2015.06.008","journal-title":"Biol Blood Marrow Transpl"},{"key":"1725_CR47","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/blood.2021011281","volume":"138","author":"M Gooptu","year":"2021","unstructured":"Gooptu M, Romee R, St. Martin A, Arora M, Al Malki M, Antin JH, et al. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021;138:273\u201382. https:\/\/doi.org\/10.1182\/blood.2021011281","journal-title":"Blood"},{"key":"1725_CR48","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1182\/blood-2019-121659","volume":"134","author":"CL Hickey","year":"2019","unstructured":"Hickey CL, Kim HT, Nikiforow S, Gooptu M, Koreth J, Ritz J, et al. Graft failure after haploidentical hematopoietic stem cell transplantation. Blood. 2019;134:4486\u20134486. https:\/\/doi.org\/10.1182\/blood-2019-121659","journal-title":"Blood"},{"key":"1725_CR49","doi-asserted-by":"publisher","first-page":"8497","DOI":"10.1002\/cam4.4353","volume":"10","author":"WR Lv","year":"2021","unstructured":"Lv WR, Zhou Y, Xu J, Fan ZP, Huang F, Xu N, et al. Haploidentical donor transplant is associated with secondary poor graft function after allogeneic stem cell transplantation: A single-center retrospective study. Cancer Med. 2021;10:8497\u2013506. https:\/\/doi.org\/10.1002\/cam4.4353","journal-title":"Cancer Med"},{"key":"1725_CR50","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/bmt.2012.239","volume":"48","author":"R Olsson","year":"2013","unstructured":"Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transpl. 2013;48:537\u201343. https:\/\/doi.org\/10.1038\/bmt.2012.239","journal-title":"Bone Marrow Transpl"},{"key":"1725_CR51","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1200\/JCO.21.02293","volume":"40","author":"L Luznik","year":"2022","unstructured":"Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, et al. Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies. J Clin Oncol. 2022;40:356\u201368. https:\/\/doi.org\/10.1200\/JCO.21.02293","journal-title":"J Clin Oncol"},{"key":"1725_CR52","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3324\/haematol.2018.189258","volume":"103","author":"D Salvatore","year":"2018","unstructured":"Salvatore D, Labopin M, Ruggeri A, Battipaglia G, Ghavamzadeh A, Ciceri F, et al. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2018;103:1317\u201328. https:\/\/doi.org\/10.3324\/haematol.2018.189258","journal-title":"Haematologica"},{"key":"1725_CR53","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/s41375-019-0686-3","volume":"34","author":"S Yu","year":"2019","unstructured":"Yu S, Huang F, Wang Y, Xu Y, Yang T, Fan Z, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2019;34:1433\u201343. https:\/\/doi.org\/10.1038\/s41375-019-0686-3","journal-title":"Leukemia"},{"key":"1725_CR54","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/S13045-017-0502-3","volume":"10","author":"YJ Chang","year":"2017","unstructured":"Chang YJ, Wang Y, Liu YR, Xu LP, Zhang X-H, Chen H, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10:134. https:\/\/doi.org\/10.1186\/S13045-017-0502-3","journal-title":"J Hematol Oncol"},{"key":"1725_CR55","doi-asserted-by":"publisher","first-page":"663.e1","DOI":"10.1016\/j.jtct.2021.04.017","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu J, Du Y, Ahmad S, Patel RD, Varela JC, Chang CC, et al. Comparison of myeloablative versus reduced-intensity conditioning regimens in allogeneic stem cell transplantation recipients with acute myelogenous leukemia with measurable residual disease-negative disease at the time of transplantation: a retrospective cohort study. Transpl Cell Ther. 2021;27:663.e1\u2013663.e6. https:\/\/doi.org\/10.1016\/j.jtct.2021.04.017","journal-title":"Transpl Cell Ther"},{"key":"1725_CR56","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","volume":"27","author":"O Ringd\u00e9n","year":"2009","unstructured":"Ringd\u00e9n O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol. 2009;27:4570\u20137. https:\/\/doi.org\/10.1200\/JCO.2008.20.9692","journal-title":"J Clin Oncol"},{"key":"1725_CR57","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154\u201361. https:\/\/doi.org\/10.1200\/JCO.2016.70.7091","journal-title":"J Clin Oncol"},{"key":"1725_CR58","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S1470-2045(12)70349-2","volume":"13","author":"M Bornh\u00e4user","year":"2012","unstructured":"Bornh\u00e4user M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13:1035\u201344. https:\/\/doi.org\/10.1016\/S1470-2045(12)70349-2","journal-title":"Lancet Oncol"},{"key":"1725_CR59","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1172\/JCI124218","volume":"129","author":"LP Wachsmuth","year":"2019","unstructured":"Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 2019;129:2357\u201373. https:\/\/doi.org\/10.1172\/JCI124218","journal-title":"J Clin Invest"},{"key":"1725_CR60","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","volume":"105","author":"C R\u00e9cher","year":"2005","unstructured":"R\u00e9cher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VMD, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2005;105:2527\u201334. https:\/\/doi.org\/10.1182\/blood-2004-06-2494","journal-title":"Blood"},{"key":"1725_CR61","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38:1273\u201383. https:\/\/doi.org\/10.1200\/JCO.19.03011","journal-title":"J Clin Oncol"},{"key":"1725_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12092339","volume":"12","author":"LM Morsink","year":"2020","unstructured":"Morsink LM, Sandmaier BM, Othus M, Palmieri R, Granot N, Bezerra ED, et al. Conditioning intensity, pre-transplant flow cytometric measurable residual disease, and outcome in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Cancers. 2020;12:1\u201318. https:\/\/doi.org\/10.3390\/cancers12092339","journal-title":"Cancers"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01725-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01725-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01725-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T11:05:14Z","timestamp":1662116714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01725-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":62,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1725"],"URL":"https:\/\/doi.org\/10.1038\/s41409-022-01725-3","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"assertion":[{"value":"7 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval and consent to participate: each center\u2019s institutional review boards approved treatment protocols according to the Declaration of Helsinki. All patients were treated according to institutional programs upon written informed consent for transplant procedures and use of medical records for research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}]}}